Boehringer Ingelheim
Private German pharma whose zongertinib became the first oral HER2 inhibitor for lung cancer.
Zongertinib (Hernexeos), brigimadlin (MDM2), DLL3×CD3 obrixtamig, KRAS pan-inhibitor programmes.
Zongertinib was the first oral HER2 inhibitor for lung cancer with HER2 mutations, approved in 2025 and moved to first line in 2026.
Afatinib (Gilotrif) is an irreversible EGFR pill for lung cancer, notable for activity against uncommon EGFR mutations (G719X, L861Q, S768I).
An anti-angiogenic pill that looked promising in mesothelioma in a small trial but failed in the large one.
Pages like this
not linked directly; found by shared links- TrialLUME-Meso
Shares Nintedanib, Mesothelioma.
- ProductSevabertinib
Shares Zongertinib, Non-small-cell lung cancer.
- InstitutionNational Taiwan University Hospital
Shares Afatinib, Non-small-cell lung cancer.
- TermPleurodesis and indwelling pleural catheter
Shares Mesothelioma, Non-small-cell lung cancer.
- ProductVinorelbine
Shares Mesothelioma, Non-small-cell lung cancer.
- TermPneumonectomy
Shares Mesothelioma, Non-small-cell lung cancer.
- PersonPatrick M. Forde
Shares Mesothelioma, Non-small-cell lung cancer.
- TermEGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)
Shares Afatinib, Non-small-cell lung cancer.